STOCK TITAN

IRIDEX (IRIX) CFO Romeo Dizon acquires 5,221 company shares in open-market buy

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IRIDEX Corporation’s Chief Financial Officer, Romeo R. Dizon, purchased additional shares of the company’s common stock. On 01/23/2026, he bought 5,221 shares at a weighted average price of $1.4779 per share, with individual trade prices ranging from $1.475 to $1.48. Following this purchase, he beneficially owns 105,661 shares of IRIDEX common stock in direct ownership. The transaction was reported as an open-market or private purchase, with full trade-level pricing details available upon request from the company, its security holders, or the SEC staff.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/23/2026 P 5,221 A $1.4779(1) 105,661 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.475 to $1.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price.
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 01/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IRIDEX (IRIX) report for its CFO?

IRIDEX (IRIX) reported that its Chief Financial Officer, Romeo R. Dizon, purchased 5,221 shares of common stock on 01/23/2026 in an open-market or private transaction.

At what price did the IRIDEX (IRIX) CFO buy shares in the latest Form 4?

The CFO’s purchase had a weighted average price of $1.4779 per share, with individual trades executed between $1.475 and $1.48 per share.

How many IRIDEX (IRIX) shares does the CFO own after this transaction?

After the reported purchase, Chief Financial Officer Romeo R. Dizon beneficially owns 105,661 shares of IRIDEX common stock in direct ownership.

Was the recent IRIDEX (IRIX) insider trade a purchase or a sale?

The Form 4 shows a transaction code "P", indicating a purchase of IRIDEX common stock by the Chief Financial Officer.

Is the IRIDEX (IRIX) CFO’s ownership classified as direct or indirect?

The Form 4 lists the CFO’s 105,661 shares as held with direct (D) ownership, with no indirect ownership entity noted in the filing.

What does the weighted average price mean in the IRIDEX (IRIX) Form 4 filing?

The filing explains that the reported price is a weighted average because the 5,221 shares were purchased in multiple trades between $1.475 and $1.48. Detailed trade-by-trade pricing is available upon request.

Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

25.61M
11.96M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW